The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blazar, B. R.
Right arrow Articles by Vallera, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blazar, B. R.
Right arrow Articles by Vallera, D. A.

The Journal of Immunology, Vol 158, Issue 1 29-39, Copyright © 1997 by American Association of Immunologists


ARTICLES

Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation

BR Blazar, PA Taylor, A Panoskaltsis-Mortari, J Buhlman, J Xu, RA Flavell, R Korngold, R Noelle and DA Vallera
Department of Pediatrics, University of Minnesota, Minneapolis 55455, USA.

Alloreactive T cells require costimulatory signals via CD40 ligand (CD40L). The tissue-destructive properties of allogeneic CD4+ but not CD8+ T cells were inhibited by anti-CD40L mAb. Fewer CD4+ thoracic duct lymphocytes (TDL) were obtained in mAb-treated recipients. Kinetic studies revealed that CD4+ T cell expansion was reduced or delayed which may account, in part, for the partial graft-vs-host disease protective effect of anti-CD40L mAb. TDL were found to have diminished anti-host-specific proliferative responses. The frequency of donor TDL and splenocytes that expressed the Th1 cytokines IL-2, IL-12 p40, and IFN-gamma mRNA was markedly diminished in mAb-treated recipients, demonstrating that Th1-driven alloresponses were susceptible to CD40L targeting. Perforin mRNA-expressing T cells were undetectable in mAb- treated recipients, consistent with reduced in vivo lethality after the adoptive transfer of allogeneic CD4+ T cells. Similar findings were observed in both B cell-replete or -deficient recipients, indicating that allogeneic T cell expansion and priming can be sustained by a non- B cell, CD40+ host cell population. Mice receiving CD40L-deficient allogeneic CD4+ T cells had survival rates comparable to the rates of those given anti-CD40L mAb treatment. Because anti-CD40L mAb also was found to prevent host anti-donor-mediated marrow allograft rejection, in vivo blockade of CD40L-CD40 interactions may provide a highly beneficial approach to improving the outcome of allogeneic bone marrow transplantation.


This article has been cited by other articles:


Home page
J. Immunol.Home page
B. Verbinnen, A. D. Billiau, J. Vermeiren, G. Galicia, D. M. A. Bullens, L. Boon, P. Cadot, G. Hens, C. Dewolf-Peeters, S. W. Van Gool, et al.
Contribution of Regulatory T Cells and Effector T Cell Deletion in Tolerance Induction by Costimulation Blockadel
J. Immunol., July 15, 2008; 181(2): 1034 - 1042.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Suzuki, X. Zheng, X. Zhang, M. Li, C. Vladau, T. E. Ichim, H. Sun, L. R. Min, B. Garcia, and W.-P. Min
Novel Vaccination for Allergy through Gene Silencing of CD40 Using Small Interfering RNA
J. Immunol., June 15, 2008; 180(12): 8461 - 8469.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. W. Hellings, A. Kasran, D. Bullens, L. Overbergh, C. Mathieu, H. Heremans, P. Matthys, L. Boon, M. Jorissen, and J. L. Ceuppens
IL-10- and IL-12-Independent Down-Regulation of Allergic Sensitization by Stimulation of CD40 Signaling
J. Immunol., October 15, 2006; 177(8): 5138 - 5144.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. E. Anderson, J. M. McNiff, D. Jain, B. R. Blazar, W. D. Shlomchik, and M. J. Shlomchik
Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ
Blood, March 1, 2005; 105(5): 2227 - 2234.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. E. Anderson, J. M. McNiff, C. Matte, I. Athanasiadis, W. D. Shlomchik, and M. J. Shlomchik
Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease
Blood, September 1, 2004; 104(5): 1565 - 1573.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. van Maurik, B. F. de St. Groth, K. J. Wood, and N. D. Jones
Dependency of Direct Pathway CD4+ T Cells on CD40-CD154 Costimulation Is Determined by Nature and Microenvironment of Primary Contact with Alloantigen
J. Immunol., February 15, 2004; 172(4): 2163 - 2170.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Zoller
Tumor Vaccination after Allogeneic Bone Marrow Cell Reconstitution of the Nonmyeloablatively Conditioned Tumor-Bearing Murine Host
J. Immunol., December 15, 2003; 171(12): 6941 - 6953.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Zhai, L. Meng, R. W. Busuttil, M. H. Sayegh, and J. W. Kupiec-Weglinski
Activation of Alloreactive CD8+ T Cells Operates Via CD4-Dependent and CD4-Independent Mechanisms and Is CD154 Blockade Sensitive
J. Immunol., March 15, 2003; 170(6): 3024 - 3028.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Andreakos, C. Smith, C. Monaco, F. M. Brennan, B. M. Foxwell, and M. Feldmann
Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction
Blood, February 1, 2003; 101(3): 983 - 991.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Gonzalez, S. A. Quezada, B. R. Blazar, A. Panoskaltsis-Mortari, A. Y. Rudensky, and R. J. Noelle
The Balance Between Donor T Cell Anergy and Suppression Versus Lethal Graft-Versus-Host Disease Is Determined by Host Conditioning
J. Immunol., November 15, 2002; 169(10): 5581 - 5589.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
S. Hummel, D. Wilms, M. Vitacolonna, and M. Zoller
Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor-bearing host
J. Leukoc. Biol., November 1, 2002; 72(5): 898 - 912.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. A. Taylor, C. J. Lees, J. M. Wilson, M. J. Ehrhardt, M. T. Campbell, R. J. Noelle, and B. R. Blazar
Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions
Blood, October 16, 2002; 100(9): 3400 - 3407.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Nguyen and B. C. Miller
CD28 Costimulation Induces {delta} Opioid Receptor Expression During Anti-CD3 Activation of T Cells
J. Immunol., May 1, 2002; 168(9): 4440 - 4445.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. A. Taylor, R. T. McElmurry, C. J. Lees, D. E. Harrison, and B. R. Blazar
Allogenic fetal liver cells have a distinct competitive engraftment advantage over adult bone marrow cells when infused into fetal as compared with adult severe combined immunodeficient recipients
Blood, March 1, 2002; 99(5): 1870 - 1872.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
M. D. Saemann, O. Parolini, G. A. Bohmig, P. Kelemen, P.-M. Krieger, J. Neumuller, K. Knarr, W. Kammlander, W. H. Horl, C. Diakos, et al.
Bacterial metabolite interference with maturation of human monocyte-derived dendritic cells
J. Leukoc. Biol., February 1, 2002; 71(2): 238 - 246.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. N. Iwakoshi, T. G. Markees, N. Turgeon, T. Thornley, A. Cuthbert, J. Leif, N. E. Phillips, J. P. Mordes, D. L. Greiner, and A. A. Rossini4
Skin Allograft Maintenance in a New Synchimeric Model System of Tolerance
J. Immunol., December 1, 2001; 167(11): 6623 - 6630.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. T. Ho and R. J. Soiffer
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Blood, December 1, 2001; 98(12): 3192 - 3204.
[Full Text] [PDF]


Home page
BloodHome page
J. Liu, B. E. Anderson, M. E. Robert, J. M. McNiff, S. G. Emerson, W. D. Shlomchik, and M. J. Shlomchik
Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease
Blood, December 1, 2001; 98(12): 3367 - 3375.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Matsue, K. Matsue, M. Kusuhara, T. Kumamoto, K. Okumura, H. Yagita, and A. Takashima
Immunosuppressive properties of CD95L-transduced "killer" hybrids created by fusing donor- and recipient-derived dendritic cells
Blood, December 1, 2001; 98(12): 3465 - 3472.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Nozawa, J. Ohata, J. Sakurai, H. Hashimoto, H. Miyajima, H. Yagita, K. Okumura, and M. Azuma
Preferential Blockade of CD8+ T Cell Responses by Administration of Anti-CD137 Ligand Monoclonal Antibody Results in Differential Effect on Development of Murine Acute and Chronic Graft-Versus-Host Diseases
J. Immunol., November 1, 2001; 167(9): 4981 - 4986.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. A. Taylor, C. J. Lees, H. Waldmann, R. J. Noelle, and B. R. Blazar
Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions
Blood, July 15, 2001; 98(2): 467 - 474.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
P. A. Taylor, R. J. Noelle, and B. R. Blazar
CD4+CD25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade
J. Exp. Med., June 4, 2001; 193(11): 1311 - 1318.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. J. Quesenberry, S. Zhong, H. Wang, and M. Stewart
Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice
Blood, January 15, 2001; 97(2): 557 - 564.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. A. Boussiotis, Z.-M. Chen, J. C. Zeller, W. J. Murphy, A. Berezovskaya, S. Narula, M. G. Roncarolo, and B. R. Blazar
Altered T-cell receptor + CD28-mediated signaling and blocked cell cycle progression in interleukin 10 and transforming growth factor-{beta}-treated alloreactive T cells that do not induce graft-versus-host disease
Blood, January 15, 2001; 97(2): 565 - 571.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S L Kalled, A H Cutler, and J L Ferrant
Long-term anti-CD154 dosing in nephritic mice is required to maintain survival and inhibit mediators of renal fibrosis
Lupus, January 1, 2001; 10(1): 9 - 22.
[Abstract] [PDF]


Home page
J. Immunol.Home page
B. R. Blazar, C. J. Lees, P. J. Martin, R. J. Noelle, B. Kwon, W. Murphy, and P. A. Taylor
Host T Cells Resist Graft-Versus-Host Disease Mediated by Donor Leukocyte Infusions
J. Immunol., November 1, 2000; 165(9): 4901 - 4909.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. C. Matthews, M. Wadhwa, C. Bird, F. E. Borras, and C. V. Navarrete
Sustained Expression of CD154 (CD40L) and Proinflammatory Cytokine Production by Alloantigen-Stimulated Umbilical Cord Blood T Cells
J. Immunol., June 15, 2000; 164(12): 6206 - 6212.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Z. Liu, K. Geboes, S. Colpaert, L. Overbergh, C. Mathieu, H. Heremans, M. de Boer, L. Boon, G. D'Haens, P. Rutgeerts, et al.
Prevention of Experimental Colitis in SCID Mice Reconstituted with CD45RBhigh CD4+ T Cells by Blocking the CD40-CD154 Interactions
J. Immunol., June 1, 2000; 164(11): 6005 - 6014.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Tsukada, H. Akiba, T. Kobata, Y. Aizawa, H. Yagita, and K. Okumura
Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation
Blood, April 1, 2000; 95(7): 2434 - 2439.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Seung, N. Iwakoshi, B. A. Woda, T. G. Markees, J. P. Mordes, A. A. Rossini, and D. L. Greiner
Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice
Blood, March 15, 2000; 95(6): 2175 - 2182.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. A. Taylor, A. Panoskaltsis-Mortari, R. J. Noelle, and B. R. Blazar
Analysis of the Requirements for the Induction of CD4+ T Cell Alloantigen Hyporesponsiveness by Ex Vivo Anti-CD40 Ligand Antibody
J. Immunol., January 15, 2000; 164(2): 612 - 622.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Rondelli, R. M. Lemoli, M. Ratta, M. Fogli, F. Re, A. Curti, M. Arpinati, and S. Tura
Rapid Induction of CD40 on a Subset of Granulocyte Colony-Stimulating Factor-Mobilized CD34+ Blood Cells Identifies Myeloid Committed Progenitors and Permits Selection of Nonimmunogenic CD40- Progenitor Cells
Blood, October 1, 1999; 94(7): 2293 - 2300.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
D. M. Harlan and A. D. Kirk
The Future of Organ and Tissue Transplantation: Can T-Cell Costimulatory Pathway Modifiers Revolutionize the Prevention of Graft Rejection?
JAMA, September 15, 1999; 282(11): 1076 - 1082.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
N. S. Kenyon, M. Chatzipetrou, M. Masetti, A. Ranuncoli, M. Oliveira, J. L. Wagner, A. D. Kirk, D. M. Harlan, L. C. Burkly, and C. Ricordi
Long-term survival and function of intrahepatic islet allografts in rhesus monkeys treated with humanized anti-CD154
PNAS, July 6, 1999; 96(14): 8132 - 8137.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari, A. H. Sharpe, and D. A. Vallera
Opposing Roles of CD28:B7 and CTLA-4:B7 Pathways in Regulating In Vivo Alloresponses in Murine Recipients of MHC Disparate T Cells
J. Immunol., June 1, 1999; 162(11): 6368 - 6377.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. E. Buhlmann, M. Gonzalez, B. Ginther, A. Panoskaltsis-Mortari, B. R. Blazar, D. L. Greiner, A. A. Rossini, R. Flavell, and R. J. Noelle
Cutting Edge: Sustained Expansion of CD8+ T Cells Requires CD154 Expression by Th Cells in Acute Graft Versus Host Disease
J. Immunol., April 15, 1999; 162(8): 4373 - 4376.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. A. ROSSINI, D. L. GREINER, and J. P. MORDES
Induction of Immunologic Tolerance for Transplantation
Physiol Rev, January 1, 1999; 79(1): 99 - 141.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. L. Beland, H. Adler, N. C. Del-Pan, W. Kozlow, J. Sung, W. Fanslow, and I. J. Rimm
Recombinant CD40L Treatment Protects Allogeneic Murine Bone Marrow Transplant Recipients From Death Caused by Herpes Simplex Virus-1 Infection
Blood, December 1, 1998; 92(11): 4472 - 4478.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Panoskaltsis-Mortari, D. L. Lacey, D. A. Vallera, and B. R. Blazar
Keratinocyte Growth Factor Administered Before Conditioning Ameliorates Graft-Versus-Host Disease After Allogeneic Bone Marrow Transplantation in Mice
Blood, November 15, 1998; 92(10): 3960 - 3967.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari, and D. A. Vallera
Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus-Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines
J. Immunol., June 1, 1998; 160(11): 5355 - 5365.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Saito, J. Sakurai, J. Ohata, T. Kohsaka, H. Hashimoto, K. Okumura, R. Abe, and M. Azuma
Involvement of CD40 Ligand-CD40 and CTLA4-B7 Pathways in Murine Acute Graft-Versus-Host Disease Induced by Allogeneic T Cells Lacking CD28
J. Immunol., May 1, 1998; 160(9): 4225 - 4231.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. L. Kalled, A. H. Cutler, S. K. Datta, and D. W. Thomas
Anti-CD40 Ligand Antibody Treatment of SNF1 Mice with Established Nephritis: Preservation of Kidney Function
J. Immunol., March 1, 1998; 160(5): 2158 - 2165.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1997 by The American Association of Immunologists, Inc. All rights reserved.